文献速递肿瘤 PET/CT

整合PRIMARY评分或SUVmax与基于MRI的风险模型对临床显著性前列腺癌检测的影响

The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-09-12

本研究将[68Ga]Ga-PSMA-11 PET/CT衍生的PRIMARY评分或SUVmax整合入基于MRI的风险计算器(RC),在683例活检初治男性中建立并验证三种逻辑回归模型。结果显示MRI-PRIMARY-RC在开发队列和验证队列中判别能力最优,可减少不必要的活检并改善临床显著性前列腺癌的早期检测。

要点

  • MRI-PRIMARY-RC在开发队列中AUC为0.924,显著高于MRI-RC的0.868和MRI-SUVmax-RC的0.904。
  • 在时间验证队列中MRI-PRIMARY-RC的AUC为0.921(95% CI:0.873-0.969),判别能力最佳。
  • 在开发与验证队列中,决策曲线分析显示MRI-PRIMARY-RC在5-40%风险阈值下净获益最大。

核心结论

  • 将PRIMARY评分加入基于MRI的多变量模型可提高活检前风险分层的准确性。
  • 作者认为新型MRI-PRIMARY预测模型是减少不必要活检并改善临床显著性前列腺癌早期检测的有前景的方法。

研究设计与样本

  • 共纳入683例连续活检初治男性,均在活检前接受[68Ga]Ga-PSMA-11 PET/CT和MRI检查。
  • 按时间分为开发队列(n=552)和时间验证队列(n=131)。
  • 开发并比较三种逻辑回归风险计算器:MRI-RC、MRI-SUVmax-RC和MRI-PRIMARY-RC,评估判别能力、校准度和临床效用。

主要发现

  • 临床显著性前列腺癌患病率在开发队列为47.5%(262/552),在时间验证队列为41.9%(55/131)。
  • 开发队列中MRI-PRIMARY-RC的AUC显著高于MRI-RC(0.924 vs. 0.868,p < 0.001)和MRI-SUVmax-RC(0.924 vs. 0.904,p = 0.002)。
  • 时间验证队列中MRI-PRIMARY-RC的AUC为0.921(95% CI:0.873-0.969),判别能力最佳。
  • Bootstrap校准曲线显示模型拟合可接受,MRI-PRIMARY-RC在0-40%范围内校准近乎完美。
  • 决策曲线分析显示,在开发与验证队列中,5-40%临床显著性前列腺癌风险阈值下MRI-PRIMARY-RC较MRI-RC和MRI-SUVmax-RC净获益最大。

关键数值与推荐

  • 开发队列中MRI-PRIMARY-RC的AUC为0.924,MRI-RC为0.868(p < 0.001),MRI-SUVmax-RC为0.904(p = 0.002)。
  • 时间验证队列中MRI-PRIMARY-RC的AUC为0.921(95% CI:0.873-0.969)。
  • 临床显著性前列腺癌风险阈值为5-40%时MRI-PRIMARY-RC净获益最大。
  • 开发队列临床显著性前列腺癌患病率为47.5%(262/552),验证队列为41.9%(55/131)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: An MRI-based risk calculator (RC) has been recommended for diagnosing clinically significant prostate cancer (csPCa). PSMA PET/CT can detect lesions that are not visible on MRI, and the addition of PSMA PET/CT to MRI may improve diagnostic performance. The aim of this study was to incorporate the PRIMARY score or SUVmax derived from [68Ga]Ga-PSMA-11 PET/CT into the RC and compare these models with MRI-based RC to assess whether this can further reduce unnecessary biopsies. METHODS: A total of 683 consecutive biopsy-naïve men who underwent both [68Ga]Ga-PSMA-11 PET/CT and MRI before biopsy were temporally divided into a development cohort (n = 552) and a temporal validation cohort (n = 131). Three logistic regression RCs were developed and compared: MRI-RC, MRI-SUVmax-RC and MRI-PRIMARY-RC. Discrimination, calibration, and clinical utility were evaluated. The primary outcome was the clinical utility of the risk calculators for detecting csPCa and reducing the number of negative biopsies. RESULTS: The prevalence of csPCa was 47.5% (262/552) in the development cohort and 41.9% (55/131) in the temporal validation cohort. In the development cohort, the AUC of MRI-PRIMARY-RC was significantly higher than that of MRI-RC (0.924 vs. 0.868, p < 0.001) and MRI-SUVmax-RC (0.924 vs. 0.904, p = 0.002). In the temporal validation cohort, MRI-PRIMARY-RC also showed the best discriminative ability with an AUC of 0.921 (95% CI: 0.873-0.969). Bootstrapped calibration curves revealed that the model fit was acceptable. MRI-PRIMARY-RC exhibited near-perfect calibration within the range of 0-40%. DCA showed that MRI-PRIMARY-RC had the greatest net benefit for detecting csPCa compared with MRI-RC and MRI-SUVmax-RC at a risk threshold of 5-40% for csPCa in both the development and validation cohorts. CONCLUSION: The addition of the PRIMARY score to MRI-based multivariable model improved the accuracy of risk stratification prior to biopsy. Our novel MRI-PRIMARY prediction model is a promising approach for reducing unnecessary biopsies and improving the early detection of csPCa.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Guo S, Ren J, Meng Q, et al. The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39264425. doi:10.1007/s00259-024-06916-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。